Insulin degludec (Tresiba) is a cost-effective alternative to insulin glargine U100 (Lantus) for patients with diabetes, and it is also likely to be more cost-effective than 2 newly marketed basal insulin analogues, including a biosimilar.
Insulin degludec (Tresiba) is a cost-effective alternative to insulin glargine U100 (Lantus) for patients with diabetes, and it is also likely to be more cost-effective than 2 newly marketed basal insulin analogues, according to a recent study funded by Novo Nordisk and published in Diabetes Therapy.
Marc Evans, MD, and colleagues used a short-term model to evaluate the costs and effects of treatment with insulin degludec versus insulin glargine over a 12-month period in patients with type 1 diabetes (T1D) and type 2 diabetes (T2D) from the perspective of the United Kingdom’sNational Health Service—that is, in light of the recent reduction in the price of insulin degludec and the addition of 2 new basal insulin analogues to the marketplace: insulin glargine U300 (Toujeo) and a biosimilar to insulin glargine U100 (Abasaglar).
The cost-effectiveness model was designed to reflect a more generalizable patient population, including patients with T2D on a basal-bolus regimen. It calculates costs associated with treatment and hypoglycemic events, and calculates quality adjusted life years by applying a disutility per hypoglycemic event.
Insulin degludec is a basal insulin with an ultra-long duration of action (more than 42 hours) and a flat and stable action profile; it has 4 times less day-to-day variation in glucose-lowering effect than insulin glargine U100. In clinical trials, insulin degludec showed equivalent reductions in glycated hemoglobin, a lower risk of hypoglycemia compared with insulin glargine U100, and a significantly lower daily dose when compared with insulin glargine U100 in T1D and T2D basal oral therapy. The researchers note that the benefits of insulin degludec have been reported in real-world clinical practice, with significant (more than 90%) reductions in hypoglycemia, and with improved glycemic control. However, in the United Kingdom, insulin glargine U100 is currently the most widely prescribed basal insulin.
The cost-utility study compared insulin degludec with insulin glargine U100 in 3 separate patient groups:
The analysis found the following:
Improvements in clinical outcomes in all 3 patient groups are a result of the reduced incidence of hypoglycemic events, the authors conclude. In patients with T1D and T2D on basal-only therapy, insulin degludec is likely to be highly cost effective versus the insulin glargine biosimilar Abasaglar, and both more effective and less costly than insulin glargine U300. In patients with T2D on a basal-bolus regimen, insulin degludec is likely to be more cost effective than either of the comparators. The study’s authors believe that insulin degludec may particularly benefit those experiencing hypoglycemia while taking other basal insulin analogues, or may prove useful to patients who would benefit from additional flexibility in their therapy.
Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials
February 10th 2024The authors of a meta-analysis assessing several disease states found no significant differences in serious adverse events, deaths, or treatment discontinuations between patients who switched from reference products to biosimilars and those who did not.
"Not So Different": How the BPCIA Transition Will Affect Biosimilar Uptake
April 10th 2020This week on the podcast, we’re speaking with the executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), Cate Lockhart, PharmD, PhD, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how the new approval pathway for biologics will affect the pace at which biosimilars come to market.
IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to Biosimilar, Generic Competition
January 18th 2024The IQVIA Institute for Human Data Science’s most recent Global Use of Medicines report projected that market introductions of new biosimilar and generic drugs will increase projected losses for originator products from $111 billion to $192 billion over the next 5 years.
IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe
January 10th 2024IQVIA’s report on the impact biosimilar competition has had on Europe’s health care space identified ongoing challenges with biosimilar access and generating savings, calling for more policies focusing on fostering a sustainable market for years to come.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.